Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseasesPLoS ONE
AbstractDespite the successes provided by vaccination, many challenges still exist with respect to controlling new and re-emerging infectious diseases. Innovative vaccine platforms composed of adaptable adjuvants able to appropriately modulate immune responses, induce long-lived immunity in a single dose, and deliver immunogens in a safe and stable manner via multiple routes of administration are needed. This work describes the development of a novel biodegradable polyanhydride nanoparticle-based vaccine platform administered as a single intranasal dose that induced long-lived protective immunity against respiratory disease caused by Yesinia pestis, the causative agent of pneumonic plague. Relative to the responses induced by the recombinant protein F1-V alone and MPLA-adjuvanted F1-V, the nanoparticle-based vaccination regimen induced an immune response that was characterized by high titer and high avidity IgG1 anti-F1-V antibody that persisted for at least 23 weeks post-vaccination. After challenge, no Y. pestis were recovered from the lungs, livers, or spleens of mice vaccinated with the nanoparticle-based formulation and histopathological appearance of lung, liver, and splenic tissues from these mice post-vaccination was remarkably similar to uninfected control mice.
RightsThis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright OwnerUlery et al.
Citation InformationBret Daniel Ulery, Devender Kumar, Amanda Ellen Ramer-Tait, Dennis W. Metzger, et al.. "Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases" PLoS ONE Vol. 6 Iss. 3 (2011) p. article no. 17642
Available at: http://works.bepress.com/balaji_narasimhan/10/